Conjugation of amino-containing drugs to polysaccharides by tosylation: amphotericin B-arabinogalactan conjugates

被引：32

作者：

Ehrenfreund-Kleinman, T

Golenser, J

Domb, AJ ^{[1
]}

机构：

[1] Hebrew Univ Jerusalem, David R Bloom Ctr Pharm, Fac Med, Sch Pharm,Dept Med Chem & Nat Prod, IL-91120 Jerusalem, Israel

[2] Hebrew Univ Jerusalem, Kuvin Ctr Study Infect Dis, IL-91120 Jerusalem, Israel

来源：

BIOMATERIALS | 2004年 / 25卷 / 15期

关键词：

arabinogalactan; amphotericin-B; tosylate; mesylate; water-soluble conjugate;

D O I：

10.1016/j.biomaterials.2003.09.080

中图分类号：

R318 [生物医学工程];

学科分类号：

0831 ;

摘要：

The coupling of amphotericin-B (AmB), a water-insoluble antifungal and antileishmanial agent, to arabinogalactan (AG) via tosylate or mesylate derivatives was investigated as a method for the conjugation of amino-containing drugs to polysaccharides. in the first step, AG was reacted with tosyl- or mesyl-chloride at different ratios to obtain tosylate or mesylate AG derivatives. AmB was conjugated to AG derivatives in either aqueous or organic media via an amine bond. AG-AmB conjugates were soluble in water and exhibited improved stability in aqueous solutions as compared to the unbound drug. The conjugates showed comparable inhibitory concentration values against the pathogenic yeast Candida albicans, and against Leishmania major parasites. They were about 60 times less hemolytic against sheep erythrocytes than the free drug, and less toxic when injected i.v. to BALB/c mice. (C) 2003 Elsevier Ltd. All rights reserved.

引用

页码：3049 / 3057

页数：9

共 36 条

[1]

Adams M. F., 1963, TAPPI, V46, P544

[2] Carrier effects on biological activity of amphotericin B [J].

Brajtburg, J ;

Bolard, J .

CLINICAL MICROBIOLOGY REVIEWS, 1996, 9 (04) :512-+

[3]

BUTLER WT, 1996, JAMA-J AM MED ASSOC, V195, P127

[4] PHARMACOKINETICS AND TOXICITY OF CONTINUOUS INFUSION AMPHOTERICIN-B IN CANCER-PATIENTS [J].

CHABOT, GG ;

PAZDUR, R ;

VALERIOTE, FA ;

BAKER, LH .

JOURNAL OF PHARMACEUTICAL SCIENCES, 1989, 78 (04) :307-310

[5] Effects of MS-8209, an amphotericin B derivative, on tumor necrosis factor alpha synthesis and human immunodeficiency virus replication in macrophages [J].

Clayette, P ;

Martin, M ;

Beringue, V ;

Dereuddre-Bosquet, N ;

Adjou, KT ;

Seman, M ;

Dormont, D .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (02) :405-407

[6] Utility of poly(ethylene glycol) conjugation to create prodrugs of amphotericin B [J].

Conover, CD ;

Zhao, H ;

Longley, CB ;

Shum, KL ;

Greenwald, RB .

BIOCONJUGATE CHEMISTRY, 2003, 14 (03) :661-666

[7] N-methyl-N-D-fructosyl amphotericin B methyl ester (MF-AME), a novel antifungal agent of low toxicity:: Monomer/micelle control over selective toxicity [J].

Cybulska, B ;

Gadomska, I ;

Mazerski, J ;

Grzybowska, J ;

Borowski, E ;

Cheron, M ;

Bolard, J .

ACTA BIOCHIMICA POLONICA, 2000, 47 (01) :121-131

[8] DRUG POLYMER CONJUGATES - POTENTIAL FOR IMPROVED CHEMOTHERAPY [J].

DUNCAN, R .

ANTI-CANCER DRUGS, 1992, 3 (03) :175-210

[9] Overview of the lipid formulations of amphotericin B [J].

Dupont, B .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 49 :31-36

[10] Synthesis and characterization of novel water soluble amphotericin B-arabinogalactan conjugates [J].

Ehrenfreund-Kleinman, T ;

Azzam, T ;

Falk, R ;

Polacheck, I ;

Golenser, J ;

Domb, AJ .

BIOMATERIALS, 2002, 23 (05) :1327-1335

← 1 2 3 4 →